Intersections between Microbiome and Heart Failure: Revisiting the Gut Hypothesis

Journal of Cardiac Failure

Volumn 21, Issue 12, 2015, Pages 973-980

  Nagatomo, Yuji ^a   Tang, W H Wilson ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

heart failure; Microbiome; TMAO

Indexed keywords

MICROBIAL ENZYME; PREBIOTIC AGENT; PROBIOTIC AGENT; TRIMETHYLAMINE OXIDE; METHYLAMINE; TRIMETHYLOXAMINE;

ANTIBIOTIC THERAPY; CARDIOVASCULAR DISEASE; HEART FAILURE; HUMAN; INFLAMMATION; INTESTINE; INTESTINE FLORA; MICROBIOME; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; DRUG EFFECTS; FEMALE; HOMEOSTASIS; MALE; METABOLISM; MICROFLORA; PHYSIOLOGY; SENSITIVITY AND SPECIFICITY;

FEMALE; GASTROINTESTINAL MICROBIOME; HEART FAILURE; HOMEOSTASIS; HUMANS; MALE; METHYLAMINES; MICROBIOTA; PROBIOTICS; SENSITIVITY AND SPECIFICITY;

EID: 84960802334     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2015.09.017     Document Type: Review

References (71)

1. A.S. Neish Microbes in gastrointestinal health and disease Gastroenterology 136 2009 65 80
2. F. Backhed, R.E. Ley, J.L. Sonnenburg, D.A. Peterson, and J.I. Gordon Host-bacterial mutualism in the human intestine Science 307 2005 1915 1920
3. J.K. Nicholson, E. Holmes, and I.D. Wilson Gut microorganisms, mammalian metabolism and personalized health care Nat Rev Microbiol 3 2005 431 438
4. M. Li, B. Wang, M. Zhang, M. Rantalainen, S. Wang, H. Zhou, and et al. Symbiotic gut microbes modulate human metabolic phenotypes Proc Natl Acad Sci U S A 105 2008 2117 2122
5. T. Yatsunenko, F.E. Rey, M.J. Manary, I. Trehan, M.G. Dominguez-Bello, M. Contreras, and et al. Human gut microbiome viewed across age and geography Nature 486 2012 222 227
6. S.R. Gill, M. Pop, R.T. Deboy, P.B. Eckburg, P.J. Turnbaugh, B.S. Samuel, and et al. Metagenomic analysis of the human distal gut microbiome Science 312 2006 1355 1359
7. P.J. Turnbaugh, R.E. Ley, M.A. Mahowald, V. Magrini, E.R. Mardis, and J.I. Gordon An obesity-associated gut microbiome with increased capacity for energy harvest Nature 444 2006 1027 1031
8. L. Wen, R.E. Ley, P.Y. Volchkov, P.B. Stranges, L. Avanesyan, A.C. Stonebraker, and et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes Nature 455 2008 1109 1113
9. F. Backhed, H. Ding, T. Wang, L.V. Hooper, G.Y. Koh, A. Nagy, and et al. The gut microbiota as an environmental factor that regulates fat storage Proc Natl Acad Sci U S A 101 2004 15718 15723
10. M.E. Dumas, R.H. Barton, A. Toye, O. Cloarec, C. Blancher, A. Rothwell, and et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice Proc Natl Acad Sci U S A 103 2006 12511 12516
11. B. Mell, V.R. Jala, A.V. Mathew, J. Byun, H. Waghulde, Y. Zhang, and et al. Evidence for a link between gut microbiota and hypertension in the Dahl rat model Physiol Genomics 47 2015 187 197
12. J. Takala Determinants of splanchnic blood flow Br J Anaesth 77 1996 50 58
13. A. Krack, B.M. Richartz, A. Gastmann, K. Greim, U. Lotze, S.D. Anker, and et al. Studies on intragastric PCO2 at rest and during exercise as a marker of intestinal perfusion in patients with chronic heart failure Eur J Heart Fail 6 2004 403 407
14. A. Sandek, I. Bjarnason, H.D. Volk, R. Crane, J.B. Meddings, J. Niebauer, and et al. Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure Int J Cardiol 157 2012 80 85
15. J.K. Hsiao, C.Y. Huang, Y.Z. Lu, C.Y. Yang, and L.C. Yu Magnetic resonance imaging detects intestinal barrier dysfunction in a rat model of acute mesenteric ischemia/reperfusion injury Invest Radiol 44 2009 329 335
16. N. Hashimoto, and H. Ohyanagi Effect of acute portal hypertension on gut mucosa Hepatogastroenterology 49 2002 1567 1570
17. A. Sandek, J. Bauditz, A. Swidsinski, S. Buhner, J. Weber-Eibel, S. von Haehling, and et al. Altered intestinal function in patients with chronic heart failure J Am Coll Cardiol 50 2007 1561 1569
18. G.P. Arutyunov, O.I. Kostyukevich, R.A. Serov, N.V. Rylova, and N.A. Bylova Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure Int J Cardiol 125 2008 240 245
19. J. Alverdy, O. Zaborina, and L. Wu The impact of stress and nutrition on bacterial-host interactions at the intestinal epithelial surface Curr Opin Clin Nutr Metab Care 8 2005 205 209
20. F. Wang, Q. Li, Q. He, Y. Geng, C. Tang, C. Wang, and et al. Temporal variations of the ileal microbiota in intestinal ischemia and reperfusion Shock 39 2013 96 103
21. M.A. Llamas, M.A. Aller, D. Marquina, M.P. Nava, and J. Arias Bacterial translocation to mesenteric lymph nodes increases in chronic portal hypertensive rats Dig Dis Sci 55 2010 2244 2254
22. X.T. Gan, G. Ettinger, C.X. Huang, J.P. Burton, J.V. Haist, V. Rajapurohitam, and et al. Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat Circ Heart Fail 7 2014 491 499
23. B. Levine, J. Kalman, L. Mayer, H.M. Fillit, and M. Packer Elevated circulating levels of tumor necrosis factor in severe chronic heart failure N Engl J Med 323 1990 236 241
24. S.D. Anker, K.R. Egerer, H.D. Volk, W.J. Kox, P.A. Poole-Wilson, and A.J. Coats Elevated soluble CD14 receptors and altered cytokines in chronic heart failure Am J Cardiol 79 1997 1426 1430
25. E. Roig, J. Orus, C. Pare, M. Azqueta, X. Filella, F. Perez-Villa, and et al. Serum interleukin-6 in congestive heart failure secondary to idiopathic dilated cardiomyopathy Am J Cardiol 82 1998 688 690 A8
26. Y. Sato, Y. Takatsu, K. Kataoka, T. Yamada, R. Taniguchi, S. Sasayama, and et al. Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation Clin Cardiol 22 1999 811 813
27. K. Maeda, T. Tsutamoto, A. Wada, N. Mabuchi, M. Hayashi, T. Tsutsui, and et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure J Am Coll Cardiol 36 2000 1587 1593
28. Y. Nagatomo, T. Yoshikawa, T. Kohno, A. Yoshizawa, T. Anzai, T. Meguro, and et al. Effects of beta-blocker therapy on high sensitivity C-reactive protein, oxidative stress, and cardiac function in patients with congestive heart failure J Card Fail 13 2007 365 371
29. D.L. Mann, J.J. McMurray, M. Packer, K. Swedberg, J.S. Borer, W.S. Colucci, and et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) Circulation 109 2004 1594 1602
30. C.J. Doig, L.R. Sutherland, J.D. Sandham, G.H. Fick, M. Verhoef, and J.B. Meddings Increased intestinal permeability is associated with the development of multiple organ dysfunction syndrome in critically ill ICU patients Am J Respir Crit Care Med 158 1998 444 451
31. I. Cirera, T.M. Bauer, M. Navasa, J. Vila, L. Grande, P. Taura, and et al. Bacterial translocation of enteric organisms in patients with cirrhosis J Hepatol 34 2001 32 37
32. E.A. Deitch Bacterial translocation or lymphatic drainage of toxic products from the gut: what is important in human beings? Surgery 131 2002 241 244
33. D.W. Riddington, B. Venkatesh, C.M. Boivin, R.S. Bonser, T.S. Elliott, T. Marshall, and et al. Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass JAMA 275 1996 1007 1012
34. A. Krack, R. Sharma, H.R. Figulla, and S.D. Anker The importance of the gastrointestinal system in the pathogenesis of heart failure Eur Heart J 26 2005 2368 2374
35. M. Ozban, C. Aydin, N. Cevahir, C. Yenisey, O. Birsen, G. Gumrukcu, and et al. The effect of melatonin on bacterial translocation following ischemia/reperfusion injury in a rat model of superior mesenteric artery occlusion BMC Surg 15 2015 18
36. J. Amar, M. Serino, C. Lange, C. Chabo, J. Iacovoni, S. Mondot, and et al. Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept Diabetologia 54 2011 3055 3061
37. J. Amar, C. Lange, G. Payros, C. Garret, C. Chabo, O. Lantieri, and et al. Blood microbiota dysbiosis is associated with the onset of cardiovascular events in a large general population: the D.E.S.I.R. study PLoS One 8 2013 e54461
38. V. Dinakaran, A. Rathinavel, M. Pushpanathan, R. Sivakumar, P. Gunasekaran, and J. Rajendhran Elevated levels of circulating DNA in cardiovascular disease patients: metagenomic profiling of microbiome in the circulation PLoS One 9 2014 e105221
39. J. Niebauer, H.D. Volk, M. Kemp, M. Dominguez, R.R. Schumann, M. Rauchhaus, and et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study Lancet 353 1999 1838 1842
40. T. Peschel, M. Schonauer, H. Thiele, S.D. Anker, G. Schuler, and J. Niebauer Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure Eur J Heart Fail 5 2003 609 614
41. V.M. Conraads, P.G. Jorens, L.S. De Clerck, H.K. Van Saene, M.M. Ieven, J.M. Bosmans, and et al. Selective intestinal decontamination in advanced chronic heart failure: a pilot trial Eur J Heart Fail 6 2004 483 491
42. W.R. Wikoff, A.T. Anfora, J. Liu, P.G. Schultz, S.A. Lesley, E.C. Peters, and et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites Proc Natl Acad Sci U S A 106 2009 3698 3703
43. P. Evenepoel, B.K. Meijers, B.R. Bammens, and K. Verbeke Uremic toxins originating from colonic microbial metabolism Kidney Int Suppl 2009 S12 S19
44. S. Yamamoto, Y. Zuo, J. Ma, P.G. Yancey, T.E. Hunley, M. Motojima, and et al. Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice Nephrol Dial Transplant 26 2011 2491 2497
45. F.C. Barreto, D.V. Barreto, S. Liabeuf, N. Meert, G. Glorieux, M. Temmar, and et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients Clin J Am Soc Nephrol 4 2009 1551 1558
46. S. Lekawanvijit, A. Adrahtas, D.J. Kelly, A.R. Kompa, B.H. Wang, and H. Krum Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J 31 2010 1771 1779
47. K. Yang, C. Wang, L. Nie, X. Zhao, J. Gu, X. Guan, and et al. Klotho protects against indoxyl sulphate-induced myocardial hypertrophy J Am Soc Nephrol 26 2015 2434 2446
48. K. Yang, X. Xu, L. Nie, T. Xiao, X. Guan, T. He, and et al. Indoxyl sulfate induces oxidative stress and hypertrophy in cardiomyocytes by inhibiting the AMPK/UCP2 signaling pathway Toxicol Lett 234 2015 110 119
49. Z. Wang, E. Klipfell, B.J. Bennett, R. Koeth, B.S. Levison, B. Dugar, and et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease Nature 472 2011 57 63
50. B.J. Bennett, T.Q. de Aguiar Vallim, Z. Wang, D.M. Shih, Y. Meng, J. Gregory, and et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation Cell Metab 17 2013 49 60
51. F.P. Martin, Y. Wang, N. Sprenger, I.K. Yap, T. Lundstedt, P. Lek, and et al. Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model Mol Syst Biol 4 2008 157
52. W.H. Tang, Z. Wang, B.S. Levison, R.A. Koeth, E.B. Britt, X. Fu, and et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk N Engl J Med 368 2013 1575 1584
53. W.H. Tang, Z. Wang, D.J. Kennedy, Y. Wu, J.A. Buffa, B. Agatisa-Boyle, and et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease Circ Res 116 2015 448 455
54. E.P. Rhee, C.B. Clish, A. Ghorbani, M.G. Larson, S. Elmariah, E. McCabe, and et al. A combined epidemiologic and metabolomic approach improves CKD prediction J Am Soc Nephrol 24 2013 1330 1338
55. J.D. Bell, J.A. Lee, H.A. Lee, P.J. Sadler, D.R. Wilkie, and R.H. Woodham Nuclear magnetic resonance studies of blood plasma and urine from subjects with chronic renal failure: identification of trimethylamine-N-oxide Biochim Biophys Acta 1096 1991 101 107
56. M.A. Bain, R. Faull, G. Fornasini, R.W. Milne, and A.M. Evans Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis Nephrol Dial Transplant 21 2006 1300 1304
57. W.H. Tang, Z. Wang, Y. Fan, B. Levison, J.E. Hazen, L.M. Donahue, and et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis J Am Coll Cardiol 64 2014 1908 1914
58. W.H. Tang, Z. Wang, K. Shrestha, A.G. Borowski, Y. Wu, R.W. Troughton, and et al. Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure J Card Fail 21 2015 91 96
59. M. Lever, P.M. George, S. Slow, D. Bellamy, J.M. Young, M. Ho, and et al. Betaine and trimethylamine-N-oxide as predictors of cardiovascular outcomes show different patterns in diabetes mellitus: an observational study PLoS One 9 2014 e114969
60. M. Ufnal, R. Jazwiec, M. Dadlez, A. Drapala, M. Sikora, and J. Skrzypecki Trimethylamine-N-oxide: a carnitine-derived metabolite that prolongs the hypertensive effect of angiotensin II in rats Can J Cardiol 30 2014 1700 1705
61. M.S. Kim, S.S. Hwang, E.J. Park, and J.W. Bae Strict vegetarian diet improves the risk factors associated with metabolic diseases by modulating gut microbiota and reducing intestinal inflammation Environ Microbiol Rep 5 2013 765 775
62. S.C. Bischoff, G. Barbara, W. Buurman, T. Ockhuizen, J.D. Schulzke, M. Serino, and et al. Intestinal permeability - a new target for disease prevention and therapy BMC Gastroenterol 14 2014 189
63. L.R. Lopetuso, F. Scaldaferri, G. Bruno, V. Petito, F. Franceschi, and A. Gasbarrini The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors Eur Rev Med Pharmacol Sci 19 2015 1068 1076
64. J.T. Grayston, R.A. Kronmal, L.A. Jackson, A.F. Parisi, J.B. Muhlestein, J.D. Cohen, and et al. Azithromycin for the secondary prevention of coronary events N Engl J Med 352 2005 1637 1645
65. C.P. Cannon, E. Braunwald, C.H. McCabe, J.T. Grayston, B. Muhlestein, R.P. Giugliano, and et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome N Engl J Med 352 2005 1646 1654
66. G.N. Kalambokis, A. Mouzaki, M. Rodi, K. Pappas, A. Fotopoulos, X. Xourgia, and et al. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites Clin Gastroenterol Hepatol 10 2012 815 818
67. V. Lam, J. Su, S. Koprowski, A. Hsu, J.S. Tweddell, P. Rafiee, and et al. Intestinal microbiota determine severity of myocardial infarction in rats FASEB J 26 2012 1727 1735
68. M. de Vrese, and J. Schrezenmeir Probiotics, prebiotics, and synbiotics Adv Biochem Eng Biotechnol 111 2008 1 66
69. A.C. Costanza, S.D. Moscavitch, H.C. Faria Neto, and E.T. Mesquita Probiotic therapy with Saccharomyces boulardii for heart failure patients: a randomized, double-blind, placebo-controlled pilot trial Int J Cardiol 179 2015 348 350
70. S. Lekawanvijit, A.R. Kompa, M. Manabe, B.H. Wang, R.G. Langham, F. Nishijima, and et al. Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate PLoS One 7 2012 e41281
71. H. Fujii, F. Nishijima, S. Goto, M. Sugano, H. Yamato, R. Kitazawa, and et al. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress Nephrol Dial Transplant 24 2009 2089 2095